0001193125-26-115123
SEC filingAcrivon Therapeutics, Inc. (ACRV), a clinical-stage biotechnology company, reported a net loss of $77.9 million for FY 2025, an improvement from $80.6 million in FY 2024, driven by reduced operating expenses of $84.1 million compared to $89.2 million prior year. Research and development expenses decreased to $60.0 million from $64.0 million, primarily due to fewer milestones in the ACR-368 program ($23.0 million vs. $34.1 million), offset by increased spending on ACR-2316 ($7.5 million vs. $3.4 million). General and administrative expenses fell to $24.1 million from $25.2 million. No revenue was generated, consistent with pre-commercial status. Other income, net, was $6.2 million, down from $8.6 million due to lower interest income. Balance sheet shows total assets of $129.7 million, with cash, cash equivalents, and investments at $118.6 million, providing runway into Q2 2027. Cash used in operations was $63.7 million, partially offset by $66.1 million from investing activities. Forward-looking, the company advances ACR-368 Phase 2b trials in endometrial cancer with 39% ORR in biomarker-positive patients and ACR-2316 Phase 1, expecting continued losses but pipeline progress.
Acrivon Therapeutics reported FY 2025 net loss of $77.9 million, improved from $80.6 million in 2024, primarily due to lower operating expenses of $84.1 million versus $89.2 million. R&D expenses declined $4.0 million to $60.0 million, driven by $11.1 million reduction in ACR-368 costs, partially offset by $4.1 million increase for ACR-2316. G&A expenses decreased $1.1 million to $24.1 million. Loss from operations was $84.1 million, improved from prior year. Other income net fell to $6.2 million from $8.6 million. Comprehensive loss was $78.2 million. Shares outstanding: 31,648,856 at year-end, weighted average 38.5 million. Total assets $129.7 million, equity $112.5 million.
No revenue generated in FY 2025 or 2024, as the company is pre-commercial with no approved products. Future revenue potential from collaborations or milestones, but none recognized.
Pre-revenue biotech with no gross or operating margins applicable. Operating loss $84.1 million reflects high R&D intensity (71% of op ex). Stock-based compensation $14.7 million in cash flow adjustments. Losses driven by clinical advancement costs, with efficiency gains YoY.
Net cash used in operations $63.7 million, improved from $65.7 million prior year. Investing provided $66.1 million from investment maturities. Financing used $0.7 million. Net cash increase $1.7 million; ending cash, equivalents, restricted $41.7 million. Total liquidity $118.6 million. Liabilities $17.2 million, low debt. Accumulated deficit $274.9 million.
Cash funds operations into Q2 2027. Priorities: Advance ACR-368 Phase 2b in endometrial cancer (39% ORR biomarker+), ACR-2316 Phase 1 (tumor shrinkage in 9/20 patients), ACR-6840 preclinical. Risks include funding needs, clinical success, regulatory approval. Expects increasing expenses for trials, no near-term profitability.